Xenetic Biosciences filings document the regulatory record for a Nasdaq-listed biopharmaceutical company developing DNase-based immuno-oncology technologies. Its Form 8-K reports cover operating and financial results, material events, capital-structure disclosures, equity incentive activity and governance matters tied to the company’s common stock.
Proxy materials describe annual meeting proposals, director elections, shareholder voting mechanics and board-related governance. The filing record also captures disclosures related to the company’s DNase program, collaboration activity, compensation arrangements, quorum and proxy-solicitation matters, and other formal updates affecting corporate reporting and stockholder approvals.
Xenetic Biosciences, Inc. (XBIO) reported third-quarter 2026 results and a proposed all-stock share exchange to acquire all outstanding share capital of Santersus AG, subject to Xenetic stockholder approval. The transaction is expected to close in the first quarter of 2027, subject to stockholder approval, Nasdaq listing approval for the shares to be issued, effectiveness of a resale registration statement on Form S-1, and other customary closing conditions.
Quarterly royalty revenue was approximately $0.7 million, down approximately 29%; research and development expense was approximately $0.5 million, down approximately 31%; and general and administrative expense rose approximately 138% to $1.9 million, primarily due to transaction-related legal and financial advisory costs. Net loss was approximately $1.7 million, or $0.72 per share, versus approximately $0.5 million, or $0.33 per share, a year earlier. Cash and cash equivalents were approximately $5.8 million as of September 30, 2026, versus approximately $7.9 million as of December 31, 2025.
The proposed combined company’s pipeline includes four first-in-class programs, with pivotal-stage programs in sepsis and systemic lupus erythematosus that have received FDA Breakthrough Device Designations. Xenetic reported the first patient dosed in a Phase I study combining systemic DNase I with anti-CD19 CAR T-cell therapy for large B-cell lymphoma; initial efficacy data are expected in the second quarter of 2027.
Xenetic Biosciences, Inc. (XBIO) agreed to acquire Santersus AG’s entire issued share capital in exchange for Xenetic common stock, subject to stockholder approval and other closing conditions. If completed, Santersus shareholders are expected to own approximately 85% of the combined company on a fully diluted basis, assuming net cash of $0 at closing; final ownership is subject to adjustments. The combined company is expected to trade on Nasdaq as Santersus Bio, Inc. under ticker SNTS, with an eight-member board: six directors designated by Santersus and two by Xenetic.
For the quarter ended September 30, 2026, royalty revenue fell 29.4% to $725,257 and net loss widened to $1,695,478 from $509,940. General and administrative expense rose 138.4% to $1,943,746, primarily due to acquisition-related legal and financial advisory services. For the nine months, net loss was $3,081,555 versus $2,101,784. Cash was $5,809,635 at September 30, 2026, and operating cash use was $2,073,997 for the nine months. Management believes existing resources will fund operations for at least 12 months from issuance of the financial statements, while anticipating a need for additional capital over the long term.
Xenetic Biosciences, Inc. (XBIO) reports that Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation each reported beneficial ownership of 55,040 common shares, equal to 2.35% of the class. Each reported sole voting and dispositive power over 55,040 shares. Certain funds managed by Renaissance Technologies LLC have the right to receive dividends and proceeds from sales of the securities.
Xenetic Biosciences (XBIO) announced an updated investor presentation for its pending share exchange transaction with Santersus AG. The proposed transaction is subject to Xenetic stockholder approval and is expected to close in Q4 2026. At closing, Santersus would become a wholly owned subsidiary and continue as the combined company’s operating business; the combined company is expected to trade on Nasdaq as SNTS. The presentation lists negotiated valuations of $21 million for Xenetic and $120 million for Santersus, with a total estimated transaction valuation of $141 million. The Xenetic valuation assumes $0 Net Cash and is subject to adjustment. It estimates Santersus shareholders would own approximately 85% and Xenetic stockholders approximately 15%, subject to adjustment, and illustrates approximately 14,552,566 new Xenetic shares issued at closing; actual issuance is determined by the Exchange Ratio.
The presentation also reports that a retrospective analysis of 10 NucleoCapture compassionate-use cases in SLE showed median SLEDAI-2K of 17.5 before and 8.0 after three treatments (p=0.009).
Xenetic Biosciences, Inc. (XBIO) is the subject of a Schedule 13G filing by MJL Manager LLC and Michael Liu reporting that they currently hold no beneficial ownership of the company’s common stock. The filing lists 0 shares beneficially owned, representing 0% of the outstanding common stock, with no sole or shared voting or dispositive power.
Xenetic Biosciences, Inc. (XBIO) entered into a Share Exchange Agreement to acquire all of the outstanding share capital of Swiss company Santersus AG in an all‑stock transaction, with Santersus becoming a wholly owned subsidiary. At closing, Santersus shareholders are expected to own approximately 85% and existing Xenetic stockholders about 15% of the combined company on a fully diluted, as‑converted basis, subject to net cash and other adjustments. The combined company is expected to be renamed Santersus Bio, Inc. and listed on the Nasdaq Capital Market under the symbol “SNTS”, with an eight‑member board (six designated by Santersus and two by Xenetic) and Santersus CEO James Ladtkow leading management. Closing is targeted for the fourth quarter of 2026 and is conditioned on Xenetic stockholder approval, effectiveness of a resale Form S‑1, Nasdaq listing approval for the new shares, and other customary conditions; Xenetic may owe a $500,000 termination fee and up to $300,000 in expense reimbursement in certain break scenarios.
Xenetic Biosciences, Inc. reported financial results for the quarter ended June 30, 2026 and highlighted progress on its proprietary DNase immuno-oncology platform. Royalty revenue for the quarter was approximately $0.7 million, up about 12% from approximately $0.6 million in the prior-year period, contributing to approximately $1.5 million in royalty revenue during the first six months of 2026.
Research and development expenses decreased to approximately $0.6 million, while general and administrative expenses rose to approximately $1.1 million, largely due to higher legal costs tied to an ongoing strategic review process. Net loss for the quarter was approximately $0.9 million. The company ended the second quarter with approximately $6.5 million in cash and cash equivalents, compared to approximately $7.9 million as of December 31, 2025, and continues to advance its DNase platform through preclinical, translational and collaborative research efforts.
Xenetic Biosciences, Inc., a pre-commercial biopharmaceutical company developing DNase-based immune-oncology therapies for difficult-to-treat solid tumors, reported Q2 2026 royalty revenue of $660,601, all from its PolyXen sublicense with Takeda. Six‑month 2026 revenue was $1,467,524, a 24.0% increase over the prior‑year period.
The company recorded a Q2 2026 net loss of $929,695 and a six‑month 2026 net loss of $1,386,077, compared with a loss of $1,591,844 in the first half of 2025. Operating expenses for the first half totaled $2,941,331, with research and development of $1,213,456 and general and administrative of $1,727,875, the latter rising mainly from legal costs tied to a strategic review.
As of June 30, 2026, Xenetic held $6,471,766 in cash, total assets of $6,967,998, current liabilities of $894,977 and working capital of approximately $5.8 million. Management believes existing resources will fund operations for at least twelve months, but additional long‑term capital will be required. All Series B preferred shares were converted into roughly 45,000 common shares, leaving no preferred outstanding and only about 800 warrants. The board is conducting a formal strategic review that may include a sale, asset sale or reverse merger, with no assurance any transaction will occur.
Xenetic Biosciences, Inc. Schedule 13G reports beneficial ownership by MJL Manager LLC and Michael Liu. MJL Manager LLC holds 93,565 shares (reported as 4.1% of the class) and Michael Liu holds 126,741 shares (5.5%), with shared voting and dispositive power reported.
The filing states Michael Liu is sole control person of MJL and both reporting persons disclaim beneficial ownership of each other’s shares except for their pecuniary interest; signatures are dated 05/29/2026.
Xenetic Biosciences, Inc. amendment reports that Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation beneficially own 137,440 shares of Common Stock, equal to 6.00% of the class. The filing notes certain funds managed by RTC have rights to dividends and sale proceeds.